ASCO Recommends Against Routine Adjuvant Chemo For Stage II Colon Cancer
Exercise Improves Function, Symptoms Of Cancer Survivors, AHRQ Report Finds
Guideline Adherence Improves Early Breast Cancer Survival
Chemosensitivity, Resistance Assays Not Ready For Clinic, ASCO Tech Assessment Says
FDA Approves Taxotere For Node+ Breast Cancer
FDA Approves Lilly’s Alimta For Metastatic NSCLC
Reduced Risk of Metastasis When Screening Finds Cancer
Ellence Has Lower Risk Of Heart Damage, Study Finds
Modality Combo Decreases Prostate Cancer Recurrence
Hormonal Therapy Improves Prostate Cancer Survival
Study Suggests Surveillance Colonoscopies Overperformed
Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Bhattacharya cancels NIH all-hands meeting
- In the Headlines: “There’s no one to stand up for NCI right now.”
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies
